Hisun Pharmaceutical
Hisun Pharmaceutical, officially known as Zhejiang Hisun Pharmaceutical Co., Ltd., is a prominent player in the global pharmaceutical industry, headquartered in CN. Founded in 1956, the company has established a strong presence in major operational regions, including Asia, Europe, and North America. Hisun Pharmaceutical focuses on the research, development, and manufacturing of a diverse range of products, including generic drugs, active pharmaceutical ingredients (APIs), and innovative therapies. With a commitment to quality and innovation, Hisun has achieved significant milestones, including numerous certifications and partnerships that enhance its market position. The company is recognised for its unique approach to drug development, particularly in oncology and cardiovascular treatments. Hisun Pharmaceutical continues to make strides in the industry, solidifying its reputation as a trusted provider of high-quality pharmaceutical solutions.
DitchCarbon Score
How does Hisun Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hisun Pharmaceutical's score of 22 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hisun Pharmaceutical's reported carbon emissions
Hisun Pharmaceutical, headquartered in China (CN), currently does not report any specific carbon emissions data, as there are no available figures for emissions in kg CO2e. Additionally, the company has not established any documented reduction targets or climate pledges, indicating a lack of formal commitments towards carbon neutrality or emissions reduction initiatives. As of now, there are no emissions inherited from a parent company or related organization, and no data cascades from other entities such as SBTi or CDP. This absence of data and commitments places Hisun Pharmaceutical in a context where it may need to enhance its climate strategy to align with industry standards and expectations for sustainability.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hisun Pharmaceutical is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
